483 related articles for article (PubMed ID: 37313239)
21. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
22. A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.
Sun K; Zhu NL; Huang SL; Qu H; Gu YP; Qin L; Liu J; Leng Y
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38789494
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease.
Imajo K; Honda Y; Yoneda M; Saito S; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):535-548. PubMed ID: 33108553
[TBL] [Abstract][Full Text] [Related]
25. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
[TBL] [Abstract][Full Text] [Related]
26. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
27. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
Harrison SA; Taub R; Neff GW; Lucas KJ; Labriola D; Moussa SE; Alkhouri N; Bashir MR
Nat Med; 2023 Nov; 29(11):2919-2928. PubMed ID: 37845512
[TBL] [Abstract][Full Text] [Related]
28. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Hu L; Gu Y; Liang J; Ning M; Yang J; Zhang Y; Qu H; Yang Y; Leng Y; Zhou B
J Med Chem; 2023 Mar; 66(5):3284-3300. PubMed ID: 36799411
[TBL] [Abstract][Full Text] [Related]
30. Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics.
Alshehade SA
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102377. PubMed ID: 38772519
[TBL] [Abstract][Full Text] [Related]
31. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
32. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
33. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
[TBL] [Abstract][Full Text] [Related]
34. Metabolic drivers of non-alcoholic fatty liver disease.
Bence KK; Birnbaum MJ
Mol Metab; 2021 Aug; 50():101143. PubMed ID: 33346069
[TBL] [Abstract][Full Text] [Related]
35. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom.
Kuchay MS; Isaacs S; Misra A
Diabetes Metab Syndr; 2024 May; 18(5):103034. PubMed ID: 38714040
[TBL] [Abstract][Full Text] [Related]
36. Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis.
Zhao C; Ji G; Zhao X; Ma T; Li Y; Wu W; Zhou L
Comb Chem High Throughput Screen; 2024 May; ():. PubMed ID: 38803181
[TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
38. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
[TBL] [Abstract][Full Text] [Related]
39. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
40. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
